LDL

Choose Selective LDL Inhibitors

LDL Products

  • All (5)
  • LDL Modulators (5)
  • New LDL Products
Catalog No. Product Name Information Product Use Citations Product Validations
S1655 Ezetimibe (SCH-58235) Ezetimibe (SCH-58235) is a potent, selective, cholesterol absorption inhibitor, used to lower cholesterol.
EMBO Mol Med, 2022, 14(2):e14903
Food Funct, 2022, 13(6):3185-3197
Mol Syst Biol, 2021, 17(8):e10239
S2119 Probucol Probucol (DH-581) is an anti-hyperlipidemic drug by lowering the level of cholesterol in the bloodstream by increasing the rate of LDL catabolism.
S2748 Anacetrapib (MK-0859) Anacetrapib (MK0859) is a potent, selective, reversible rhCETP and mutant CETP(C13S) inhibitor with IC50 of 7.9 nM and 11.8 nM, increases HDL-C and decreases LDL-C, does not increase aldosterone or blood pressure. Phase 3.
Circulation, 2021, 143(9):921-934
J Phys Chem B, 2016, 120(33):8254-63
Atherosclerosis, 2014, 235(2):449-62
S7953 ETC-1002 ETC-1002 (Bempedoic acid, ESP-55016),also known as Bempedoic acid, is an orally available, once-daily LDL-C lowering small molecule designed to lower elevated levels of LDL-C and to avoid side effects associated with existing LDL-C lowering therapies.ETC-1002 is an activator of hepatic AMP-activated protein kinase (AMPK). It has potent inhibitory activity against hepatic ATP-citrate lyase(IC50=29 uM).
Biomed Pharmacother, 2021, 144:112325
J Cell Mol Med, 2020, 25
S9187 Phillygenin Phillygenin (Sylvatesmin), a bioactive intergradient in Osmanthus fragrans, has anti-inflammatory, anti-obesity and antipyretic activities. It could reduce blood lipid levels and low density lipoprotein.
S1655 Ezetimibe (SCH-58235) Ezetimibe (SCH-58235) is a potent, selective, cholesterol absorption inhibitor, used to lower cholesterol.
EMBO Mol Med, 2022, 14(2):e14903
Food Funct, 2022, 13(6):3185-3197
Mol Syst Biol, 2021, 17(8):e10239
S2119 Probucol Probucol (DH-581) is an anti-hyperlipidemic drug by lowering the level of cholesterol in the bloodstream by increasing the rate of LDL catabolism.
S2748 Anacetrapib (MK-0859) Anacetrapib (MK0859) is a potent, selective, reversible rhCETP and mutant CETP(C13S) inhibitor with IC50 of 7.9 nM and 11.8 nM, increases HDL-C and decreases LDL-C, does not increase aldosterone or blood pressure. Phase 3.
Circulation, 2021, 143(9):921-934
J Phys Chem B, 2016, 120(33):8254-63
Atherosclerosis, 2014, 235(2):449-62
S7953 ETC-1002 ETC-1002 (Bempedoic acid, ESP-55016),also known as Bempedoic acid, is an orally available, once-daily LDL-C lowering small molecule designed to lower elevated levels of LDL-C and to avoid side effects associated with existing LDL-C lowering therapies.ETC-1002 is an activator of hepatic AMP-activated protein kinase (AMPK). It has potent inhibitory activity against hepatic ATP-citrate lyase(IC50=29 uM).
Biomed Pharmacother, 2021, 144:112325
J Cell Mol Med, 2020, 25
S9187 Phillygenin Phillygenin (Sylvatesmin), a bioactive intergradient in Osmanthus fragrans, has anti-inflammatory, anti-obesity and antipyretic activities. It could reduce blood lipid levels and low density lipoprotein.
Tags: LDL modulation | LDL modulator | LDL regulation| LDL review